Neoadjuvant bevacizumab in combination with chemotherapy could become a new standard for Her2 negative breast cancer if the improvement of pCR can be translated in an improvement of long term outcome and if predictive markers can be found to reduce the number needed to treat. This evidence concerns the gene ERBB2 and breast carcinoma.